vs
碧迪（BDX）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是Revvity的6.8倍（$5.3B vs $772.1M），Revvity净利率更高（12.7% vs 7.3%，领先5.5%），Revvity同比增速更快（5.9% vs -0.4%），碧迪自由现金流更多（$549.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs 2.0%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BDX vs RVTY — 直观对比
营收规模更大
BDX
是对方的6.8倍
$772.1M
营收增速更快
RVTY
高出6.2%
-0.4%
净利率更高
RVTY
高出5.5%
7.3%
自由现金流更多
BDX
多$387.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
2.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $772.1M |
| 净利润 | $382.0M | $98.4M |
| 毛利率 | 45.9% | — |
| 营业利润率 | 10.5% | 14.5% |
| 净利率 | 7.3% | 12.7% |
| 营收同比 | -0.4% | 5.9% |
| 净利润同比 | 24.0% | 3.9% |
| 每股收益（稀释后） | $1.34 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXRVTY
| Q4 25 | $5.3B | $772.1M | ||
| Q3 25 | $5.9B | $698.9M | ||
| Q2 25 | $5.5B | $720.3M | ||
| Q1 25 | $5.3B | $664.8M | ||
| Q4 24 | $5.2B | $729.4M | ||
| Q3 24 | $5.4B | $684.0M | ||
| Q2 24 | $5.0B | $691.7M | ||
| Q1 24 | $5.0B | $649.9M |
净利润BDXRVTY
| Q4 25 | $382.0M | $98.4M | ||
| Q3 25 | $493.0M | $46.7M | ||
| Q2 25 | $574.0M | $53.9M | ||
| Q1 25 | $308.0M | $42.2M | ||
| Q4 24 | $303.0M | $94.6M | ||
| Q3 24 | $400.0M | $94.4M | ||
| Q2 24 | $487.0M | $55.4M | ||
| Q1 24 | $537.0M | $26.0M |
毛利率BDXRVTY
| Q4 25 | 45.9% | — | ||
| Q3 25 | 47.5% | 53.6% | ||
| Q2 25 | 47.8% | 54.5% | ||
| Q1 25 | 42.8% | 56.5% | ||
| Q4 24 | 43.2% | — | ||
| Q3 24 | 45.7% | 56.3% | ||
| Q2 24 | 46.2% | 55.7% | ||
| Q1 24 | 45.7% | 54.6% |
营业利润率BDXRVTY
| Q4 25 | 10.5% | 14.5% | ||
| Q3 25 | 11.8% | 11.7% | ||
| Q2 25 | 16.0% | 12.6% | ||
| Q1 25 | 10.4% | 10.9% | ||
| Q4 24 | 8.8% | 16.3% | ||
| Q3 24 | 11.4% | 14.3% | ||
| Q2 24 | 12.1% | 12.4% | ||
| Q1 24 | 14.5% | 6.8% |
净利率BDXRVTY
| Q4 25 | 7.3% | 12.7% | ||
| Q3 25 | 8.4% | 6.7% | ||
| Q2 25 | 10.4% | 7.5% | ||
| Q1 25 | 5.8% | 6.4% | ||
| Q4 24 | 5.9% | 13.0% | ||
| Q3 24 | 7.4% | 13.8% | ||
| Q2 24 | 9.8% | 8.0% | ||
| Q1 24 | 10.6% | 4.0% |
每股收益（稀释后）BDXRVTY
| Q4 25 | $1.34 | $0.86 | ||
| Q3 25 | $1.71 | $0.40 | ||
| Q2 25 | $2.00 | $0.46 | ||
| Q1 25 | $1.07 | $0.35 | ||
| Q4 24 | $1.04 | $0.77 | ||
| Q3 24 | $1.37 | $0.77 | ||
| Q2 24 | $1.68 | $0.45 | ||
| Q1 24 | $1.85 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $25.3B | $7.3B |
| 总资产 | $54.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BDXRVTY
| Q4 25 | $740.0M | $919.9M | ||
| Q3 25 | $641.0M | $931.4M | ||
| Q2 25 | $735.0M | $991.8M | ||
| Q1 25 | $667.0M | $1.1B | ||
| Q4 24 | $711.0M | $1.2B | ||
| Q3 24 | $1.7B | $1.2B | ||
| Q2 24 | $4.5B | $2.0B | ||
| Q1 24 | $2.3B | $1.7B |
股东权益BDXRVTY
| Q4 25 | $25.3B | $7.3B | ||
| Q3 25 | $25.4B | $7.4B | ||
| Q2 25 | $25.5B | $7.6B | ||
| Q1 25 | $25.2B | $7.6B | ||
| Q4 24 | $25.2B | $7.7B | ||
| Q3 24 | $25.9B | $7.9B | ||
| Q2 24 | $25.9B | $7.9B | ||
| Q1 24 | $25.6B | $7.8B |
总资产BDXRVTY
| Q4 25 | $54.8B | $12.2B | ||
| Q3 25 | $55.3B | $12.1B | ||
| Q2 25 | $54.9B | $12.4B | ||
| Q1 25 | $54.5B | $12.4B | ||
| Q4 24 | $54.7B | $12.4B | ||
| Q3 24 | $57.3B | $12.8B | ||
| Q2 24 | $55.6B | $13.4B | ||
| Q1 24 | $54.2B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.5% | 21.0% |
| 资本支出强度资本支出/营收 | 2.1% | 2.6% |
| 现金转化率经营现金流/净利润 | 1.72× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $2.6B | $509.4M |
8季度趋势，按日历期对齐
经营现金流BDXRVTY
| Q4 25 | $657.0M | $182.0M | ||
| Q3 25 | $1.4B | $138.5M | ||
| Q2 25 | $1.2B | $134.3M | ||
| Q1 25 | $164.0M | $128.2M | ||
| Q4 24 | $693.0M | $174.2M | ||
| Q3 24 | $1.2B | $147.9M | ||
| Q2 24 | $1.3B | $158.6M | ||
| Q1 24 | $514.0M | $147.6M |
自由现金流BDXRVTY
| Q4 25 | $549.0M | $161.8M | ||
| Q3 25 | $1.0B | $120.0M | ||
| Q2 25 | $1.0B | $115.5M | ||
| Q1 25 | $35.0M | $112.2M | ||
| Q4 24 | $588.0M | $149.8M | ||
| Q3 24 | $882.0M | $125.6M | ||
| Q2 24 | $1.1B | $136.6M | ||
| Q1 24 | $380.0M | $129.7M |
自由现金流率BDXRVTY
| Q4 25 | 10.5% | 21.0% | ||
| Q3 25 | 17.0% | 17.2% | ||
| Q2 25 | 19.0% | 16.0% | ||
| Q1 25 | 0.7% | 16.9% | ||
| Q4 24 | 11.4% | 20.5% | ||
| Q3 24 | 16.2% | 18.4% | ||
| Q2 24 | 22.4% | 19.7% | ||
| Q1 24 | 7.5% | 20.0% |
资本支出强度BDXRVTY
| Q4 25 | 2.1% | 2.6% | ||
| Q3 25 | 6.0% | 2.6% | ||
| Q2 25 | 3.2% | 2.6% | ||
| Q1 25 | 2.4% | 2.4% | ||
| Q4 24 | 2.0% | 3.4% | ||
| Q3 24 | 5.4% | 3.3% | ||
| Q2 24 | 3.6% | 3.2% | ||
| Q1 24 | 2.7% | 2.7% |
现金转化率BDXRVTY
| Q4 25 | 1.72× | 1.85× | ||
| Q3 25 | 2.75× | 2.97× | ||
| Q2 25 | 2.12× | 2.49× | ||
| Q1 25 | 0.53× | 3.03× | ||
| Q4 24 | 2.29× | 1.84× | ||
| Q3 24 | 2.94× | 1.57× | ||
| Q2 24 | 2.66× | 2.87× | ||
| Q1 24 | 0.96× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
